Hypolipemic activity of ITA 104
Vilageliu, J.; Zapatero, M.D.; Bruseghini, L.
Archivos de Farmacologia y Toxicologia 4(1): 135-136
1978
ISSN/ISBN: 0304-8616 PMID: 697379 Document Number: 129528
Document emailed within 1 workday
Related Documents
Rodríguez, L.; Roser, R.; Palacios, G.; Sagarra, R.; Esteve, A. 1979: Hypolipemic activity of piperazine sultosylate (A-585) in the rat and chicken Archivos de Farmacologia y Toxicologia 5(3): 272-274Marmo, E.; Lampa, E.; Matera, M.G.; Spadaro, R.; Romano, A.R.; Guarino, V. 1984: On the hypolipemic properties of bendaline Journal of Medicine 15(2): 105-125
Delarge, J.; Ghys, A. 1983: Some 4-phenylthiopyridine-3-sulfonamides with hypolipemic properties Annales Pharmaceutiques Francaises 41(1): 55-60
Schüller, A. 1974: Concept and systematization of the hypolipemic syndromes Revista Clinica Espanola 132(5): 399-404
Harvengt, C.; Heller, F. 1988: Does hypolipemic treatment predispose to colonic cancer? Acta Gastro-Enterologica Belgica 51(6): 521-524
Chadarevian, R.; Bruckert, E.; Turpin, G. 1997: Hypolipemic agents and prevention of coronary disease Annales de Cardiologie et d'Angeiologie 46(2): 89-98
Fernández-Miranda, C.; Aranda, I.L. 1999: Necessity of hypolipemic treatment in patients with coronary disease Medicina Clinica 112(11): 438
Vilaseca Canais, J.; Buxeda Mestres, C.; Cámara Contreras, C.; Flor Serra, F.; Pérez Guinaldo, R.; Sánchez Viñas, M. 1997: Do the patients we treat with hypolipemic drugs have a coronary risk? Atencion Primaria 20(1): 49-53
Tessari, F.; Caparrotta, L.; Gaion, R.M.; Fassina, G. 1981: Effect of cyclonicate, a new hypolipemic drug, on lipolysis in vitro Il Farmaco; Edizione Scientifica 36(12): 1029-1036
Vivancos-Mora, J.; León-Colombo, T.; Monforte-Dupret, C. 1999: Hypolipemic treatment in the prevention of atherosclerotic plaque complications Revista de Neurologia 29(9): 857-863
Pérez Corral, F.; Perales, J.; Fraile, G. 1990: The hypolipemic effect of concentrated salmon oil rich in n-3 fatty acids Anales de Medicina Interna 7(6): 299-303
Sovová, M.; Sova, P. 2004: Pharmaceutical importance of Allium sativum L. 5. Hypolipemic effects in vitro and in vivo Ceska a Slovenska Farmacie: Casopis Ceske Farmaceuticke Spolecnosti a Slovenske Farmaceuticke Spolecnosti 53(3): 117-123
Marmo, E.; Imperatore, A.M.; Caputi, A.; Cataldi, S. 1971: Hypocholesteremic and hypolipemic effects of p-chlorophenoxy-alpha-isobutyrate of 3-hydroxymethylpyridine hydrochloride Il Farmaco; Edizione Pratica 26(10): 557-584
Miturzyńska-Stryjecka, H.; Widomska-Czekajska, T.; Bielak, G.; Grossmann, G. 1994: Assessment of hypolipemic action of the preparation olbetam in people with primary hypercholesterolemia Wiadomosci Lekarskie 47(15-16): 566-569
Fabre, J.; Denizot, M.; Wildi, E.; Micheli, H.; Berthoud, S. 1973: Hypolipemic property and myotoxic action of clofibrate in a case of nephrotic syndrome Schweizerische Rundschau für Medizin Praxis 62(23): 732-737
Sznajderman, M. 1984: Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV Przeglad Lekarski 41(7): 493-499
Farnier, M. 1992: The "duration of administration" factor in studies of clinical pharmacology of hypolipemic drugs Archives des Maladies du Coeur et des Vaisseaux 85(Special Issue 2): 113-115
Kalmykova, V.I.; Nikitina, E.K.; Bezzubov, A.A. 1986: Comparative study of the action of hypolipemic and antioxidant drugs in ischemic heart disease Sovetskaia Meditsina 3: 81-84
Barretto, A.C.; Wajngarten, M.; Gebara, O.C.; do Serro Azul, J.B.; Pierri, H.; Nussbacher, A.; Pivotto, L.; Bellotti, G.; Pileggi, F. 1996: Risk factors in elderly patients selected by primary care physicians for hypolipemic treatment Arquivos Brasileiros de Cardiologia 67(2): 93-98
Cailleux, A.; Allain, P.; Tadei, A. 1976: Pharmacokinetic study in man of hypolipemic agents derived from clofibric acid after single and repeated administration Therapie 31(5): 637-645